BRIDGEWATER, N.J., Oct. 28, 2020 (GLOBE NEWSWIRE) — VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”) today announced that it will report its financial results for the third quarter ended September 30, 2020, on Thursday, November 5, 2020, before the market opens. VYNE will host a conference call and webcast at 8:30 a.m. Eastern Time to discuss the financial results and provide a corporate update. Conference Call       Thursday, November 5th @ 8:30am Eastern Time Toll Free:     800-289-0438 International:     323-794-2423 Conference ID:     9576782 Webcast:     http://public.viavid.com/index.php?id=142196 A replay of the…

BRIDGEWATER, N.J., Oct. 28, 2020 (GLOBE NEWSWIRE) — VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”) today announced that it will report its financial results for the third quarter ended September 30, 2020, on Thursday, November 5, 2020, before the market opens. VYNE will host a conference call and webcast at 8:30 a.m. Eastern Time to discuss the financial results and provide a corporate update. Conference Call       Thursday, November 5th @ 8:30am Eastern Time Toll Free:     800-289-0438 International:     323-794-2423 Conference ID:     9576782 Webcast:     http://public.viavid.com/index.php?id=142196 A replay of the…

BRIDGEWATER, N.J., Oct. 07, 2020 (GLOBE NEWSWIRE) — VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”) today announced a coverage update for its novel ZILXI™ (minocycline) topical foam, 1.5%. ZILXI is the first minocycline product of any form to be FDA approved for use in rosacea for the treatment of inflammatory lesions in adults and is just recently available in pharmacies nationwide. Express Scripts, one of the nation’s leading pharmacy benefit managers (PBMs), has elected to cover ZILXI effective October 2, 2020 on Express Scripts’ National Preferred, Flex, and Basic commercial formularies, representing millions of additional covered lives in the…

BRIDGEWATER, N.J., Oct. 07, 2020 (GLOBE NEWSWIRE) — VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”) today announced a coverage update for its novel ZILXI™ (minocycline) topical foam, 1.5%. ZILXI is the first minocycline product of any form to be FDA approved for use in rosacea for the treatment of inflammatory lesions in adults and is just recently available in pharmacies nationwide. Express Scripts, one of the nation’s leading pharmacy benefit managers (PBMs), has elected to cover ZILXI effective October 2, 2020 on Express Scripts’ National Preferred, Flex, and Basic commercial formularies, representing millions of additional covered lives in the…

BRIDGEWATER, N.J., Oct. 07, 2020 (GLOBE NEWSWIRE) — VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”) today announced a coverage update for its novel ZILXI™ (minocycline) topical foam, 1.5%. ZILXI is the first minocycline product of any form to be FDA approved for use in rosacea for the treatment of inflammatory lesions in adults and is just recently available in pharmacies nationwide. Express Scripts, one of the nation’s leading pharmacy benefit managers (PBMs), has elected to cover ZILXI effective October 2, 2020 on Express Scripts’ National Preferred, Flex, and Basic commercial formularies, representing millions of additional covered lives in the…